US Pharma MarketingThe post Rocket points to Danon gene therapy’s safety after Phase II protocol change appeared first on Clinical Trials Arena.
Rocket points to Danon gene therapy’s safety after Phase II protocol change
Three patients with Danon disease have safely received Rocket's RP-A501, with no cases of capillary leak syndrome observed thus far. The post Rocket points to Danon gene therapy’s safety after Phase II protocol change appeared first on Clinical Trials Arena .
Three patients with Danon disease have safely received Rocket's RP-A501, with no cases of capillary leak syndrome observed thus far.
Source: Clinical Trials Arena